Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-020-0399-6
Abstract: The optimal duration of therapy in patients receiving immune-checkpoint inhibitors (ICIs) is a new but crucial question that has arisen owing to the observation of durable remissions in >85% of patients with metastatic melanoma who… read more here.
Keywords: melanoma; long term; treatment; immunotherapy discontinuation ... See more keywords